netFormulary NHS
Cambridgeshire and Peterborough
Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Section
Notes:

THIS CHAPTER IS CURRENTLY UNDER REVIEW. FOR FURTHER ADVICE PLEASE CONTACT YOUR LEAD PHARMACIST OR CCG MEDICINES OPTIMISATION TEAM (PRIMARY CARE ENQUIRIES ONLY)

Formulary and commissioned oncology and haematology regimens

From April 2013 cancer treatments listed on the National Cancer Drug Fund list are funded through the NHS England as outlined on their dedicated website.

Treatments recommended in a NICE Technology Appraisal will be added to Formulary but may not always be provided at all centres (Some centres may not see the cohort of patients the NICE Technology Appraisal covers)

For patient information about chemotherapy and chemotherapy regimens, please see the Macmillan cancer support website: 

Royal Papworth Hospital NHS Foundation Trust does not routinely administer chemotherapy and does not have facilities for the preparation of injectable cytotoxic medication. If a patient requires treatment, usual practice is to transfer to an alternative hospital able to provide this service. The Trust accepts that an occasion may arise where transfer of the patient gives cause for concern. In this situation the Consultant wishing to prescribe cytotoxic medication must discuss the case directly with the Chief Pharmacist.

 Useful Links
Numbers in brackets indicate counts of (Formulary items, Non Formulary items)
08.01 Cytotoxic drugs (1,0)
Side-effects of cytotoxic drugs (0,0)
Drugs for cytotoxic-induced side-effects (3,5)
08.01.01 Alkylating drugs (9,3)
08.01.02 Anthracyclines and other cytotoxic antibiotics (10,1)
08.01.03 Antimetabolites (16,4)
08.01.04 Vinca alkaloids and etoposide (5,5)
08.01.05 Other antineoplastic drugs (90,17)
08.02 Drugs affecting the immune response (1,0)
Immunosuppressant therapy (0,0)
08.02.01 Antiproliferative immunosuppressants (3,0)
08.02.02 Corticosteroids and other immunosuppressants (11,1)
08.02.03 Anti-lymphocyte monoclonal antibodies (8,0)
08.02.04 Other immunomodulating drugs (8,4)
Interferon Alfa (3,1)
Interferon beta (3,1)
Interferon gamma (1,0)
Aldesleukin (1,0)
BCG bladder instillation (0,0)
Canakinumab (0,0)
Dimethyl fumarate (0,0)
Fingolimod (0,0)
Glatiramer acetate (1,0)
Histamine (0,0)
Lenalidomide, pomalidomide, and thalidomide (0,0)
Mifamurtide (1,0)
Natalizumab (1,0)
Teriflunomide (0,0)
08.03 Sex hormones and hormone antagonists in malignant disease (0,0)
08.03.01 Oestrogens (2,0)
08.03.02 Progestogens (3,0)
08.03.03 Androgens (0,0)
08.03.04 Hormone antagonists (0,0)
08.03.04.01 Breast cancer (6,2)
08.03.04.02 Prostate cancer and gonadorelin analogues (1,0)
Gonadorelin analogues (1,0)
Anti-androgens (9,2)
Gonadotrophin-releasing hormone antagonists (0,0)
08.03.04.03 Somatostatin analogues (4,0)
netFormulary